Clinical research compliance alert: Common Rule updated, effective date delayed

Bricker Graydon LLP
Contact

Bricker & Eckler LLP

The U.S. Department of Health and Human Services has delayed the effective and compliance date for the updates to the Common Rule for six months from January 19, 2018, until July 19, 2018. The updates make significant changes to informed consent that entities involved in government-funded clinical research involving human subjects must heed.

The general requirements for informed consent remain the same, with the addition of a “reasonable person” standard for judging information provided to subjects. In addition, the updates require that the informed consent process (and consent form) begin with “key information,” covering five factors, to assist subjects in understanding the implications of their participation.

The eight “basic elements” of consent still apply, with an additional requirement concerning the collection of identifiable private information (IPI) or identifiable biospecimens for future research. There are also three new requirements added to the six “additional elements” of consent, related to the use of biospecimens for commercial profit, the disclosure of clinically relevant research results to subjects and use of whole genome sequencing.

The updates also include five new subsections. These subsections (1) add a “broad consent” option, allowing prospective consent for unspecified future uses of IPI and identifiable biospecimens; (2) add a new waiver or alteration of consent for qualifying research involving public benefit; (3) include major revisions to the general waiver or alteration of consent conditions, adding new criteria for research involving IPI or identifiable biospecimens; (4) provide an exception to the consent requirement in the context of screening for recruitment purposes; and (5) require that researchers post clinical trial consent forms on a public federal website.

As to the actual consent forms, the updates now allow the use of electronic signatures where a written copy is also provided and include an additional waiver of documentation for subjects that do not sign documents according to cultural norms.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Bricker Graydon LLP | Attorney Advertising

Written by:

Bricker Graydon LLP
Contact
more
less

Bricker Graydon LLP on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide